Academic Rank:
Professor
Affiliation(s):
Vancouver General Hospital
Location:
Vancouver General Hospital

Short Bio:

Together with my colleagues in the Genetic Pathology Evaluation Center, we have taken advantage of the excellent patient outcome data available through the British Columbia Cancer Agency to create tissue microarrays (TMAs) that have allowed for examination of large numbers of cases of breast cancer, ovarian cancer, endometrial cancer and other cancer types, correlating immunostaining and FISH results with patient outcomes.

Starting with a presentation to the International Society of Gynecological Pathology annual meeting, and subsequently published in the society journal as a review article (Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol. 2004;23:200-5), I have advanced the hypothesis that ovarian cancer subtypes, recognizable based on histopathological examination, are distinct diseases, with different risk factors, genetic events during oncogenesis, precursor lesions, natural history, and response to chemotherapy. We founded a local ovarian carcinoma research group, OvCaRe, and have shown that these subtypes can be reproducibly diagnosed by surgical pathologists and are studying the subtype specific molecular abnormalities in these tumors. This has been my primary academic focus for the past 5 years. This is a subject of clinical import as we move towards subtype specific treatment of ovarian carcinoma. More recently the gynecological cancer focus has expanded to include uterine and vulvar cancers.

Academic Backgrounds:
  • Fellow of the Royal College of Physicians and Surgeons of Canada (Anatomical Pathology)
  • MD cum laude, Dalhousie University, Medicine. 1982
  • BSc, University of New Brunswick. 1978
Selected Publications
  • Kwon JS, McAlpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, Gilks CB, Huntsman DG. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol. 2015 Feb;125(2):338-45.
  • Kulic I, Robertson G, Chang L, Baker JH, Lockwood WW, Mok W, Fuller M, Fournier M, Wong N, Chou V, Robinson MD, Chun HJ, Gilks B, Kempkes B, Thomson TA, Hirst M, Minchinton AI, Lam WL, Jones S, Marra M, Karsan A. Loss of the Notch effector RBPJ promotes tumorigenesis. J Exp Med. 2015 Jan 12;212(1):37-52.
  • Torlakovic EE, Nielsen S, Francis G, Garratt J, Gilks B, Goldsmith JD, Hornick JL, Hyjek E, Ibrahim M, Miller K, Petcu E, Swanson PE, Zhou X, Taylor CR, Vyberg M. Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):1-18.
  • So WK, Cheng JC, Fan Q, Wong AS, Huntsman DG, Gilks CB, Leung PC. Loss of Sprouty2 in human high-grade serous ovarian carcinomas promotes EGF-induced E-cadherin down-regulation and cell invasion. FEBS Lett. 2015 Jan 30;589(3):302-9.
  • Chiang S, Staats PN, Senz J, Kommoss F, De Nictolis M, Huntsman DG, Gilks CB, Oliva E. FOXL2 Mutation is Absent in Uterine Tumors Resembling Ovarian Sex Cord Tumors. Am J Surg Pathol. 2015 Jan 9. [Epub ahead of print].
  • McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, McAlpine JN. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol. 2015 Jan 28. [Epub ahead of print].
  • Singh N, Gilks CB, Wilkinson N, McCluggage WG. Assessment of a new system for primary site assignment in high-grade serous carcinoma of fallopian tube, ovary and peritoneum. Histopathology. 2015 Jan 14. [Epub ahead of print].
  • Tone AA, McConechy MK, Yang W, Ding J, Yip S, Kong E, Wong KK, Gershenson DM, Mackay H, Shah S, Gilks B, Tinker AV, Clarke B, McAlpine JN, Huntsman D. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer. 2014 Dec 18;14:982.
  • Gilks CB, Irving J, Köbel M, Lee C, Singh N, Wilkinson N, McCluggage WG. Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases: Further Evidence for the Tubal Origin of High-grade Serous Carcinomas. Am J Surg Pathol. 2014 Dec 16. [Epub ahead of print].
  • Hanna WM, Barnes PJ, Chang MC, Gilks CB, Magliocco AM, Rees H, Quenneville L, Robertson SJ, SenGupta SK, Nofech-Mozes S. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study. J Clin Oncol. 2014 Dec 10;32(35):3967-73.
Research:
  • Breast and Gynecological Pathology
  • Teaching Pathology, Surgery and Obstetrics and Gynecology Residents
  • Development of Pathology labs for the GI/Nutrition block of the new medical school curriculum
  • Cancer